In conclusion, the simultaneous inhibition of multiple tumor-relevant genes in combination with conventional therapies—such as the siRNA-mediated knockdown of Bcl-xL plus survivin together with subsequent mitomycin C or cisplatin therapy—represents a promising option for improving bladder cancer treatment. The gene discussed is BIRC5; the disease is urinary bladder carcinoma.